Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction

Open access

Abstract

Protein–protein interactions (PPIs) governing the recognition of substrates by E3 ubiquitin ligases are critical to cellular function. There is significant therapeutic potential in the development of small molecules that modulate these interactions; however, rational design of small molecule enhancers of PPIs remains elusive. Herein, we report the prospective identification and rational design of potent small molecules that enhance the interaction between an oncogenic transcription factor, β-Catenin, and its cognate E3 ligase, SCF β-TrCP . These enhancers potentiate the ubiquitylation of mutant β-Catenin by β-TrCP in vitro and induce the degradation of an engineered mutant β-Catenin in a cellular system. Distinct from PROTACs, these drug-like small molecules insert into a naturally occurring PPI interface, with contacts optimized for both the substrate and ligase within the same small molecule entity. The prospective discovery of ‘molecular glue’ presented here provides a paradigm for the development of small molecule degraders targeting hard-to-drug proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09358-9

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of small molecule enhancers of β-catenin:β-TrCP interaction. a β-TrCP complex was titrated against 5 nM BODIPY-TMR-labeled β-catenin peptide (residues 17–48) of various phosphorylation status and binding was monitored by fluorescence polarization. Binding affinities were estimated by curve fitting to a one-site binding model. Circled on the pSer33/Ser37 β-catenin binding curve is the β-TrCP concentration that results in 20% binding saturation, which was used in the HTS. b Binding enhancement for all compounds screened in the HTS using the FP assay. Each dot represents an individual compound, with NRX-1532 highlighted. c Chemical structure of the enhancers, NRX-1532 and NRX-1933. d Enhancement of pSer33/Ser37 β-catenin peptide binding to β-TrCP with increasing concentrations of NRX-1532. In each assay, the concentration of either β-TrCP or β-catenin was adjusted to obtain 20% binding saturation in the absence of compound. Shown is a representative experiment, values reported are averages
Fig. 1 Identification of small molecule enhancers of β-catenin:β-TrCP interaction. a β-TrCP complex was titrated against 5 nM BODIPY-TMR-labeled β-catenin peptide (residues 17–48) of various phosphorylation status and binding was monitored by fluorescence polarization. Binding affinities were estimated by curve fitting to a one-site binding model. Circled on the pSer33/Ser37 β-catenin binding curve is the β-TrCP concentration that results in 20% binding saturation, which was used in the HTS. b Binding enhancement for all compounds screened in the HTS using the FP assay. Each dot represents an individual compound, with NRX-1532 highlighted. c Chemical structure of the enhancers, NRX-1532 and NRX-1933. d Enhancement of pSer33/Ser37 β-catenin peptide binding to β-TrCP with increasing concentrations of NRX-1532. In each assay, the concentration of either β-TrCP or β-catenin was adjusted to obtain 20% binding saturation in the absence of compound. Shown is a representative experiment, values reported are averagesCC BY · PubMed Central
Fig. 2 NRX-1933 binds at the pSer33/Ser37 β-catenin:β-TrCP interface and potentiates the binding affinity of the interaction. a Overall structure of NRX-1933 (yellow spheres) bound to the β-catenin:β-TrCP complex (PDB: 6M93) (Supplementary Table 1). b Unbiased Fo-Fc electron density for NRX-1933 at 3.0 standard deviations above the mean is shown (green). The compound is shown as sticks (yellow), bound between the surface of the β-TrCP β-propeller (gray) and the monophosphorylated β-catenin degron peptide, shown as sticks (magenta). c Cutaway view of the hydrophobic pocket formed by residues Leu472 and Ala434 from β-TrCP and Ile35 and Leu31 from β-catenin. d Side view of the same interaction with the β-TrCP surface removed, highlighting the β-catenin and β-TrCP residues that interact with NRX-1933. e The binding affinities of the pSer33/Ser37 and pSer33/pSer37 β-catenin peptides for β-TrCP were measured in the TR-FRET assay by titrating BODIPY-FL-labeled β-catenin peptides (residues 17-48) against 300 pM β-TrCP at varying concentrations of NRX-1532. The binding curves for the pSer33/pSer37 β-catenin peptide titrations were fitted to one-site binding model. For the pSer33/Ser37 β-catenin peptide titrations, which do not reach saturation owing to limitations in the maximum amount of fluorophore compatible with this assay. Curves were fitted to the same one-site binding model, with the upper plateau constrained to that of the pSer33/pSer37 β-catenin peptide binding curve. The KDs are reported for both pSer33/Ser37 and pSer33/pSer37 β-catenin peptides
Fig. 2 NRX-1933 binds at the pSer33/Ser37 β-catenin:β-TrCP interface and potentiates the binding affinity of the interaction. a Overall structure of NRX-1933 (yellow spheres) bound to the β-catenin:β-TrCP complex (PDB: 6M93) (Supplementary Table 1). b Unbiased Fo-Fc electron density for NRX-1933 at 3.0 standard deviations above the mean is shown (green). The compound is shown as sticks (yellow), bound between the surface of the β-TrCP β-propeller (gray) and the monophosphorylated β-catenin degron peptide, shown as sticks (magenta). c Cutaway view of the hydrophobic pocket formed by residues Leu472 and Ala434 from β-TrCP and Ile35 and Leu31 from β-catenin. d Side view of the same interaction with the β-TrCP surface removed, highlighting the β-catenin and β-TrCP residues that interact with NRX-1933. e The binding affinities of the pSer33/Ser37 and pSer33/pSer37 β-catenin peptides for β-TrCP were measured in the TR-FRET assay by titrating BODIPY-FL-labeled β-catenin peptides (residues 17-48) against 300 pM β-TrCP at varying concentrations of NRX-1532. The binding curves for the pSer33/pSer37 β-catenin peptide titrations were fitted to one-site binding model. For the pSer33/Ser37 β-catenin peptide titrations, which do not reach saturation owing to limitations in the maximum amount of fluorophore compatible with this assay. Curves were fitted to the same one-site binding model, with the upper plateau constrained to that of the pSer33/pSer37 β-catenin peptide binding curve. The KDs are reported for both pSer33/Ser37 and pSer33/pSer37 β-catenin peptidesCC BY · PubMed Central
Fig. 3 Optimized enhancers potentiate pSer33/S37A β-catenin binding and ubiquitylation. a Chemical structure of optimized enhancers and their potency in TR-FRET assay against pSer33/S37A β-catenin peptide for β-TrCP binding. b Structures of enhancers (yellow) in complex with β-catenin peptide (magenta) and β-TrCP (gray). The binding poses and β-catenin degron conformations shown for NRX-2663 (PDB: 6M92) and NRX-103094 (6M91) are from crystal structures (Supplementary Table 1), whereas the NRX-252114 pose was determined by computational docking. c Binding affinities of the β-catenin peptides (as indicated) for β-TrCP were measured in the TR-FRET assay in presence of enhancers at concentration indicated. For NRX-252114, the binding assay is bottoming out due to 300 pM β-TrCP concentration, with the curve fit yielding a higher than expected hill slope of 1.8. Therefore, the KD reported for NRX-252114 represents an upper estimate. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line with a KD of 2 nM. d 4 μM of fluorescently-labeled β-catenin peptide (residues 17–60; as indicated) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34 and 100 nM SCFβ-TrCP with increasing concentration of enhancers. β-Catenin ubiquitylation were resolved by SDS-PAGE and imaged for fluorescence
Fig. 3 Optimized enhancers potentiate pSer33/S37A β-catenin binding and ubiquitylation. a Chemical structure of optimized enhancers and their potency in TR-FRET assay against pSer33/S37A β-catenin peptide for β-TrCP binding. b Structures of enhancers (yellow) in complex with β-catenin peptide (magenta) and β-TrCP (gray). The binding poses and β-catenin degron conformations shown for NRX-2663 (PDB: 6M92) and NRX-103094 (6M91) are from crystal structures (Supplementary Table 1), whereas the NRX-252114 pose was determined by computational docking. c Binding affinities of the β-catenin peptides (as indicated) for β-TrCP were measured in the TR-FRET assay in presence of enhancers at concentration indicated. For NRX-252114, the binding assay is bottoming out due to 300 pM β-TrCP concentration, with the curve fit yielding a higher than expected hill slope of 1.8. Therefore, the KD reported for NRX-252114 represents an upper estimate. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line with a KD of 2 nM. d 4 μM of fluorescently-labeled β-catenin peptide (residues 17–60; as indicated) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34 and 100 nM SCFβ-TrCP with increasing concentration of enhancers. β-Catenin ubiquitylation were resolved by SDS-PAGE and imaged for fluorescenceCC BY · PubMed Central
Fig. 4 Enhancers potentiate binding and ubiquitylation of the unphosphorylated β-catenin degron. a Binding of Ser33/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in absence or presence of 20 μM NRX-252114. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. b Ubiquitylation of Ser33/S37A β-catenin peptide (residues 17–60) by SCFβ-TrCP in the presence of NRX-252114 under conditions similar to Fig. 3d. c 400 nM purified full-length S37A mutant β-catenin protein was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, and 400 nM SCFβ-TrCP with the increasing concentration of NRX-252114. Reactions were resolved by SDS-PAGE and analyzed by immuno-blotting with a β-catenin C-terminal antibody. For reference, ubiquitylation of WT β-catenin protein is also shown (* refers to degradation products)
Fig. 4 Enhancers potentiate binding and ubiquitylation of the unphosphorylated β-catenin degron. a Binding of Ser33/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in absence or presence of 20 μM NRX-252114. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. b Ubiquitylation of Ser33/S37A β-catenin peptide (residues 17–60) by SCFβ-TrCP in the presence of NRX-252114 under conditions similar to Fig. 3d. c 400 nM purified full-length S37A mutant β-catenin protein was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, and 400 nM SCFβ-TrCP with the increasing concentration of NRX-252114. Reactions were resolved by SDS-PAGE and analyzed by immuno-blotting with a β-catenin C-terminal antibody. For reference, ubiquitylation of WT β-catenin protein is also shown (* refers to degradation products)CC BY · PubMed Central
Fig. 5 Enhancers potentiate binding and ubiquitylation of S33E/S37A phosphomimetic β-catenin. a Schematic of the proposed phosphorylation cascade for WT and S37A, S33E/S37A mutant β-catenin. b Binding curve of S33E/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in absence or presence of 40 μM NRX-103094. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. c 4 μM of fluorescently-labeled S33E/S37A β-catenin peptide (residues 17–60) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, 100 nM SCFβ-TrCP, and 20 μM NRX-103094. Reactions were resolved by SDS-PAGE and imaged for fluorescence. d 400 nM purified full-length β-catenin protein (as indicated) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, 400 nM SCFβ-TrCP, and 20 μM NRX-103094. Reactions were resolved by SDS-PAGE and analyzed by immuno-blotting with a β-catenin C-terminal antibody (* refers to degradation products). e Enhancer potencies for S33E/S37A β-catenin peptide binding to β-TrCP. Due to low intrinsic binding affinity, the pSer33/pSer37 β-catenin binding assays were carried out at 1% binding saturation. f Binding curve of S33E/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in presence of varying NRX-252114 concentration. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. g Ubiquitylation of full-length S33E/S37A β-catenin protein in the presence of varying concentration of NRX-252114 (as described above; * refers to degradation products)
Fig. 5 Enhancers potentiate binding and ubiquitylation of S33E/S37A phosphomimetic β-catenin. a Schematic of the proposed phosphorylation cascade for WT and S37A, S33E/S37A mutant β-catenin. b Binding curve of S33E/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in absence or presence of 40 μM NRX-103094. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. c 4 μM of fluorescently-labeled S33E/S37A β-catenin peptide (residues 17–60) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, 100 nM SCFβ-TrCP, and 20 μM NRX-103094. Reactions were resolved by SDS-PAGE and imaged for fluorescence. d 400 nM purified full-length β-catenin protein (as indicated) was ubiquitylated in the presence of 125 nM Ube1, ATP, 1.75 μM Cdc34, 400 nM SCFβ-TrCP, and 20 μM NRX-103094. Reactions were resolved by SDS-PAGE and analyzed by immuno-blotting with a β-catenin C-terminal antibody (* refers to degradation products). e Enhancer potencies for S33E/S37A β-catenin peptide binding to β-TrCP. Due to low intrinsic binding affinity, the pSer33/pSer37 β-catenin binding assays were carried out at 1% binding saturation. f Binding curve of S33E/S37A β-catenin peptide for β-TrCP measured in the TR-FRET assay in presence of varying NRX-252114 concentration. For reference, the binding curve for pSer33/pSer37 β-catenin peptide in the same TR-FRET assay is represented in dotted gray line. g Ubiquitylation of full-length S33E/S37A β-catenin protein in the presence of varying concentration of NRX-252114 (as described above; * refers to degradation products)CC BY · PubMed Central
Fig. 6 Enhancers degrade S33E/S37A phosphomimetic β-catenin protein in cells. a Purified Myc/FLAG-tagged β-catenin protein (as indicated) was mixed with HEK293T cell lysates in the presence of varying amounts of NRX-252114 and immunoprecipitated using anti-myc beads. The samples were resolved on SDS-PAGE and analyzed by immuno-blotting with either C-terminal β-catenin or β-TrCP antibody. In lane 3, 2 μM β-catenin was phosphorylated with the mix of 1 μM GSK3, 200 nM CK1 and 50 nM Axin prior to its addition to the lysate. In lane 8, 6.4 μM pSer33/pSer37 β-catenin peptide was spiked into the lysate prior to the addition of β-catenin protein. b HEK293T cells without (lanes 1 and 2) or with overexpression of S33E/S37A Myc/FLAG-tagged β-catenin (lanes 3-6) were treated with NRX-252114 for 6 h (as indicated). Cells were then lysed, β-catenin was immunoprecipitated using anti-myc beads and probed for either β-catenin or β-TrCP (as described above). In lane 2, cell lysate was spiked with phosphorylated WT Myc/FLAG-tagged β-catenin protein, whereas in lane 6, the lysate was spiked with 20 μM NRX-252114 as positive controls. c HEK293T cells stably expressing Myc/FLAG-tagged S33E/S37A β-catenin were treated with varying concentrations of NRX-252114 (as indicated) for 6hrs and examined for S33E/S37A β-catenin levels by western analysis using anti-FLAG antibody. For control, Actin levels were monitored using anti-Actin antibody. For co-treatments, either 5 μM of Nedd8 E1 inhibitor (NAEi) or 10 μM of proteasome inhibitor (MG132) were added to cells 30 min prior to the compound treatment. d Same as Fig. 6c, except NRX-252262 was used
Fig. 6 Enhancers degrade S33E/S37A phosphomimetic β-catenin protein in cells. a Purified Myc/FLAG-tagged β-catenin protein (as indicated) was mixed with HEK293T cell lysates in the presence of varying amounts of NRX-252114 and immunoprecipitated using anti-myc beads. The samples were resolved on SDS-PAGE and analyzed by immuno-blotting with either C-terminal β-catenin or β-TrCP antibody. In lane 3, 2 μM β-catenin was phosphorylated with the mix of 1 μM GSK3, 200 nM CK1 and 50 nM Axin prior to its addition to the lysate. In lane 8, 6.4 μM pSer33/pSer37 β-catenin peptide was spiked into the lysate prior to the addition of β-catenin protein. b HEK293T cells without (lanes 1 and 2) or with overexpression of S33E/S37A Myc/FLAG-tagged β-catenin (lanes 3-6) were treated with NRX-252114 for 6 h (as indicated). Cells were then lysed, β-catenin was immunoprecipitated using anti-myc beads and probed for either β-catenin or β-TrCP (as described above). In lane 2, cell lysate was spiked with phosphorylated WT Myc/FLAG-tagged β-catenin protein, whereas in lane 6, the lysate was spiked with 20 μM NRX-252114 as positive controls. c HEK293T cells stably expressing Myc/FLAG-tagged S33E/S37A β-catenin were treated with varying concentrations of NRX-252114 (as indicated) for 6hrs and examined for S33E/S37A β-catenin levels by western analysis using anti-FLAG antibody. For control, Actin levels were monitored using anti-Actin antibody. For co-treatments, either 5 μM of Nedd8 E1 inhibitor (NAEi) or 10 μM of proteasome inhibitor (MG132) were added to cells 30 min prior to the compound treatment. d Same as Fig. 6c, except NRX-252262 was usedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 218

Metadata

Authors
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., Kuriyan, J., Rape, M., Cardozo, M., Gallop, M. A., Bence, N. F., Barsanti, P. A., & Saha, A.
Affiliations
  • Nurix (United States) (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Simonetta, Kyle R.
  • Saha, Anjanabha
Venue
Nature Communications
Published
2019-03-29
Volume
10
Issue
1
Pages
1402-1402
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2928048394
Cited by
217
References
44
Citations by year
2026: 36 · 2025: 42 · 2024: 35 · 2023: 27 · 2022: 23 · 2021: 25 · 2020: 27 · 2019: 2
FWCI
6.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
E3 ubiquitin ligase, β-catenin, molecular glues, small-molecule degraders, PROTACs, ubiquitination, protein degradation, oncogenic transcription factor, rational drug design
MeSH terms
Humans, Phosphorylation, Protein Binding, Substrate Specificity, Ubiquitin-Protein Ligases, beta-Transducin Repeat-Containing Proteins, beta Catenin, Small Molecule Libraries, Ubiquitination, HEK293 Cells, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. https://app.cochat.ai/papers/10.1038/s41467-019-09358-9
The paper
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., Kuriyan, J., Rape, M., Cardozo, M., Gallop, M. A., Bence, N. F., Barsanti, P. A., & Saha, A. (2019). Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nature Communications. https://doi.org/10.1038/s41467-019-09358-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.